Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resi… Read more
Formosa Pharmaceuticals, Inc. (6838) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.018x
Based on the latest financial reports, Formosa Pharmaceuticals, Inc. (6838) has a cash flow conversion efficiency ratio of -0.018x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-26.99 Million) by net assets (NT$1.51 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Formosa Pharmaceuticals, Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Formosa Pharmaceuticals, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Formosa Pharmaceuticals, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Formosa Pharmaceuticals, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Komelon Corporation
KQ:049430
|
0.017x |
|
Dry Cell and Storage Battery JSC
VN:PAC
|
N/A |
|
Samsung Pharm
KO:001360
|
-0.013x |
|
Nicolas Correa SA
MC:NEA
|
0.080x |
|
Bharat Rasayan Limited
NSE:BHARATRAS
|
0.000x |
|
Nelly Group AB
ST:NELLY
|
0.125x |
|
DocGo Inc
NASDAQ:DCGO
|
0.006x |
|
ERBUD S.A. INH. ZY-10
F:9DP
|
N/A |
Annual Cash Flow Conversion Efficiency for Formosa Pharmaceuticals, Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Formosa Pharmaceuticals, Inc. from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.55 Billion | NT$-128.68 Million | -0.083x | +51.65% |
| 2023-12-31 | NT$1.14 Billion | NT$-196.04 Million | -0.172x | +76.79% |
| 2022-12-31 | NT$467.40 Million | NT$-346.15 Million | -0.741x | +12.05% |
| 2021-12-31 | NT$393.23 Million | NT$-331.13 Million | -0.842x | -- |